# IMNN-001

Source: https://onco.cc/drugs/imnn-001/  
OnCo record `imnn-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMNN-001 is an experimental interleukin-12 DNA plasmid immunotherapy from Imunon, in phase 3 trials for advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

## Summary

IMNN-001 (GEN-1) is an interleukin-12 DNA plasmid immunotherapy (TheraPlas lipopolymer) from Imunon. A plasmid encoding interleukin-12, formulated with a PEG-PEI-cholesterol lipopolymer and given into the abdomen (intraperitoneally) with chemotherapy. Its furthest stage is phase 3, for advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. ClinicalTrials.gov registers it in 4 studies linked below. Phase 3 OVATION 3 (NCT06915025) recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-03
- Also known as: GEN-1
- Tags: pipeline; ctgov-ingest
- Code: IMNN-001
- Modality: Interleukin-12 DNA plasmid immunotherapy (TheraPlas lipopolymer)
- Mechanism: A plasmid encoding interleukin-12, formulated with a PEG-PEI-cholesterol lipopolymer and given into the abdomen (intraperitoneally) with chemotherapy.

## Sources

- Imunon: imunon.com: https://imunon.com/pipeline/
- Imunon: imunon.com: https://imunon.com/pipeline/
- Imunon: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06915025
- ClinicalTrials.gov: trials of IMNN-001: https://clinicaltrials.gov/search?intr=IMNN-001

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Imunon](https://onco.cc/companies/imunon/)
- trials: [Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat](https://onco.cc/trials/nct06915025/), [Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://onco.cc/trials/nct05739981/), [Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)](https://onco.cc/trials/nct03393884/), [Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer](https://onco.cc/trials/nct02480374/)

---
JSON: https://onco.cc/api/v1/entities/imnn-001.json